Structures by: Bond A. D.
Total: 533
5,15-bis(4-cyanophenyl)-2,8,12,18-tetrahexyl-3,7,13,17-tetramethylporphyrin, chloroform solvate (1/2)
C62H76N6,2(CHCl3)
Crystal Growth & Design (2002) 2, 1 27
a=6.9810(3)Å b=14.874(1)Å c=15.408(1)Å
α=107.095(3)° β=98.703(4)° γ=92.845(4)°
Pridopidine hydrochloride form I
C15H24NO2S,Cl
Crystal Growth & Design (2012) 12, 6 2961
a=10.4668(4)Å b=23.0660(9)Å c=6.9667(2)Å
α=90.00° β=90.00° γ=90.00°
Pridopidine hydrochloride form II
C15H24NO2S,Cl
Crystal Growth & Design (2012) 12, 6 2961
a=12.2441(4)Å b=13.4701(4)Å c=10.2207(3)Å
α=90.00° β=91.117(1)° γ=90.00°
Felodipine IV
C18H19Cl2NO4
Crystal Growth & Design (2012) 12, 8 4022
a=11.1129(9)Å b=12.5688(11)Å c=13.4969(11)Å
α=90.00° β=107.009(4)° γ=90.00°
Amlodipine besylate dihydrate
C26H35ClN2O10S
Crystal Growth & Design (2010) 10, 12 5279
a=19.1100(17)Å b=9.6240(9)Å c=16.6930(18)Å
α=90.000(10)° β=106.690(9)° γ=90.000(10)°
Amlodipine besylate dihydrate
C26H35ClN2O10S
Crystal Growth & Design (2010) 10, 12 5279
a=18.892(2)Å b=9.5070(6)Å c=16.357(3)Å
α=90.000° β=105.285(12)° γ=90.000°
Amlodipine besylate monohydrate
C20H26ClN2O5,C6H5SO3,H2O
Crystal Growth & Design (2010) 10, 12 5279
a=17.689(2)Å b=17.533(7)Å c=36.843(11)Å
α=90.0° β=90.182(17)° γ=90.0°
Trisbiimdazolecobalt(III) trisoxalatocobaltate(III) dihydrate
C18H18CoN123,C6CoO123,2(H2O)
Crystal Growth & Design (2009) 9, 6 2821
a=12.004(3)Å b=18.280(5)Å c=13.625(3)Å
α=90° β=96.839(8)° γ=90°
Trisbiimdazolecobalt(III) trisoxalatochromate(III) dihydrate
C18H18CoN123,C6CrO123,2(H2O)
Crystal Growth & Design (2009) 9, 6 2821
a=12.0595(4)Å b=18.4539(6)Å c=13.5995(5)Å
α=90.00° β=97.710(1)° γ=90.00°
Trisbiimdazolecobalt(III)tris(3-hydroxycyclobut-3-ene-1,2-dion-4-olate)hydrate
C18H18CoN123,3(C4HO4),2(H2O)
Crystal Growth & Design (2009) 9, 6 2821
a=10.1255(9)Å b=13.9169(5)Å c=14.6328(5)Å
α=118.386(1)° β=100.462(1)° γ=99.392(1)°
Trisbiimdazolecobalt(III) oxalate chloride hydrate
C18H18CoN123,C2O42,Cl,5.5(H2O)
Crystal Growth & Design (2009) 9, 6 2821
a=14.0103(8)Å b=20.9727(10)Å c=21.3754(11)Å
α=90.00° β=106.979(3)° γ=90.00°
Sodium naproxen tetrahydrate
C14H13O3,Na,4(H2O)
Crystal Growth & Design (2013) 13, 8 3665
a=40.819(5)Å b=5.5540(5)Å c=7.0928(7)Å
α=90.00° β=98.086(4)° γ=90.00°
Mu-fluorido-bis(difluorido-1,4,7-trimethyltriazacyclononane-manganese(III)) hexafluorophosphate
C18H42F5Mn2N6,F6P
Inorganic chemistry (2014) 53, 10 5013-5019
a=7.3362(5)Å b=7.4467(6)Å c=13.8751(10)Å
α=75.658(3)° β=81.412(3)° γ=72.302(3)°
C16H12ClF2N2Ru,F6P
C16H12ClF2N2Ru,F6P
Dalton transactions (Cambridge, England : 2003) (2019) 48, 20 6910-6920
a=8.0630(5)Å b=8.3719(5)Å c=13.8505(11)Å
α=104.378(3)° β=95.336(3)° γ=96.409(3)°
C17H14ClF2N2Ru,F6P
C17H14ClF2N2Ru,F6P
Dalton transactions (Cambridge, England : 2003) (2019) 48, 20 6910-6920
a=7.1872(3)Å b=11.6858(4)Å c=11.9743(4)Å
α=99.964(2)° β=97.263(2)° γ=101.058(2)°
C114H90Li4N12OZn2,2(C7H8)
C114H90Li4N12OZn2,2(C7H8)
Journal of the Chemical Society, Dalton Transactions (2001) 21 3173
a=17.4711(5)Å b=24.7419(8)Å c=24.2561(7)Å
α=90.00° β=90.718(2)° γ=90.00°
C17H21N4O2Mn,ClO4,H2O
C17H21N4O2Mn,ClO4,H2O
Dalton transactions (Cambridge, England : 2003) (2011) 40, 15 3849-3858
a=9.1700(8)Å b=12.5805(11)Å c=19.3814(17)Å
α=76.431(2)° β=81.763(2)° γ=75.643(2)°
C40H45Mn2N6O5,1.15(ClO4),0.85(C2H3N)
C40H45Mn2N6O5,1.15(ClO4),0.85(C2H3N)
Dalton transactions (Cambridge, England : 2003) (2011) 40, 13 3336-3345
a=12.1472(5)Å b=22.0062(10)Å c=16.9073(7)Å
α=90.00° β=96.2780(10)° γ=90.00°
C19H18N,Br,0.25(CHCl3)
C19H18N,Br,0.25(CHCl3)
Chemical communications (Cambridge, England) (2007) 31 3273-3275
a=14.3387(3)Å b=14.3387(3)Å c=20.4479(8)Å
α=90.00° β=90.00° γ=120.00°
C4H12N22,2(C7H5O2)
C4H12N22,2(C7H5O2)
CrystEngComm (2009) 11, 3 444-453
a=8.346(2)Å b=8.243(2)Å c=24.679(6)Å
α=90.00° β=90.00° γ=90.00°
C7H6O2,C4H5N3
C7H6O2,C4H5N3
CrystEngComm (2009) 11, 3 444-453
a=5.3467(4)Å b=17.2757(13)Å c=11.5764(9)Å
α=90.00° β=90.980(3)° γ=90.00°
Felodipine : 4,4'-bipyridine (1:1)
C18H19Cl2NO4,C10H8N2
CrystEngComm (2014) 16, 29 6603
a=36.197(3)Å b=36.436(3)Å c=8.0228(6)Å
α=90° β=90° γ=90°
Celecoxib 1,3-dimethyltetrahydropyrimidin-2(1H)-one monosolvate
C17H14F3N3O2S,C6H12N2O
Acta Crystallographica Section C (2020) 76, 7
a=12.4495(17)Å b=8.7822(13)Å c=22.656(3)Å
α=90° β=97.861(5)° γ=90°
Α-Pinene
C10H16
Acta Crystallographica Section E (2001) 57, 11 o1039-o1040
a=7.1944(6)Å b=7.5920(3)Å c=15.9190(15)Å
α=90.00° β=90.00° γ=90.00°
2(C7H9FN),I4Pb2
2(C7H9FN),I4Pb2
Journal of the American Chemical Society (2020)
a=8.7325(2)Å b=9.2819(2)Å c=27.7240(6)Å
α=90° β=97.7423(9)° γ=90°
072-1
C24H14N4O4
The Journal of organic chemistry (2014) 79, 1 41-64
a=19.8575(9)Å b=7.0316(3)Å c=27.9026(13)Å
α=90.00° β=90.00° γ=90.00°
C24H26F12N4P2,C6H16N,Cl
C24H26F12N4P2,C6H16N,Cl
Journal of the American Chemical Society (2019) 141, 22 8807-8815
a=8.5938(3)Å b=12.6025(5)Å c=18.7895(7)Å
α=90.270(2)° β=98.808(2)° γ=103.186(2)°
C92H80Cu2N12O10Zn22,C14H10Cl4O4Zn22,2(C2H3N)
C92H80Cu2N12O10Zn22,C14H10Cl4O4Zn22,2(C2H3N)
Inorganic Chemistry (2007) 46, 2224-2236
a=11.0806(7)Å b=12.5195(8)Å c=19.8843(13)Å
α=97.482(3)° β=96.817(3)° γ=98.501(3)°
C224H278N12Ni2P2Ru,2(CHCl3)
C224H278N12Ni2P2Ru,2(CHCl3)
Inorganic Chemistry (2003) 42, 6564-6574
a=13.686(3)Å b=17.442(3)Å c=23.210(5)Å
α=73.884(3)° β=80.580(3)° γ=89.957(3)°
C48H56N24O16Sn7
C48H56N24O16Sn7
Inorganic Chemistry (2002) 41, 1492-1501
a=12.779(6)Å b=12.754(7)Å c=13.155(5)Å
α=91.91(3)° β=115.07(2)° γ=117.10(4)°
Felodipine III
C18H19Cl2NO4
Crystal Growth & Design (2012) 12, 8 4022
a=15.1255(18)Å b=7.2302(9)Å c=17.2796(19)Å
α=90.00° β=110.198(7)° γ=90.00°
[{MeAs(NHCy)(NCy)}ZnMe]2
C28H58As2N4Zn2
Organometallics (2001) 20, 22 4454
a=8.1835(5)Å b=9.8676(5)Å c=23.3327(8)Å
α=81.031(3)° β=81.754(3)° γ=66.919(2)°
C10H16
C10H16
Acta Crystallographica Section E (2001) 57, 11 o1039-o1040
a=7.1944(6)Å b=7.5920(3)Å c=15.9190(15)Å
α=90° β=90° γ=90°